|
 |
| home > epc > Autumn 2003 |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC |
 |
| |
|
|
Julia Lloyd-Parks reviews the articles featured in the Autumn issue
|
|
|
|
|
The pharmaceutical sales process is riddled with inefficiencies and the productivity of individual sales teams has fallen. Thomas Hennlich, Senior Manager, and Andrys Aardema, Consultant in Customer Relationship Management, at Deloitte Consulting, consider Changing the Approach to Selling Pharmaceuticals
|
|
|
| In Make or Buy? A Strategic Assessment of the Benefits of Outsourcing, Blair McCallum, Head of McKinsey & Company's Production System Design Centre (PSDC), advises manufacturers not to regard outsourcing as a panacea for every ill |
|
|
| Integrating e-business partnerships between regulatory authorities and industry will face initial difficulties. Dr Peter-Christoph Schulz, Safety Officer at Bayer Vital GmbH, suggests some solutions, in e-Business in Pharmacovigilance |
|
|
|
| In How are Research and Clinical Trials Governed? Jo Wilson, European Director of Marsh Healthcare Services, explains why proper control, regulation and governance are essential to ensure quality research and clinical trials in health and social care |
|
|
| The pharmaceutical industry is under enormous pressure to develop and produce novel therapies as quickly as possible. Nicky Dodsworth, Director of Quality Assurance at Pharm-Olam International (UK) Ltd, investigates the opportunities in Central and Eastern Europe: Quality and Quantity |
|
|
| In Recruiting HIV Infected Patients for Anti-Retroviral Clinical Trials in CEE and the Russian Federation, Stefan Comhaire, Project Manager at Medisearch International, outlines the mutual benefit for patients and the pharmaceutical industry |
|
|
| Patient recruitment remains one of the key challenges faced by the pharmaceutical industry today. Tom Ruane, Director of Patient Recruitment & Retention at Quintiles, considers Establishing the Patient Recruitment Algorithm - Should we Apply a more Heuristic Approach? |
|
|
| Pietro Bonacossa, Marketing Executive, and Dr Faiz Kermani, Budgets, Proposals and Marketing Executive at Chiltern International Inc, examine why patients do not fully comply with their treatments and how this problem can be addressed, in Driving Patient Compliance |
|
|
| Patient diaries constitute one of the most relevant sources of direct information in clinical research. In Patient Diaries: A Possible Source of Data Inconsistency?, Sebastian Pacios Merino, Vice President of Operations, Countries Group, PRA International, identifies the perils and pitfalls |
|
|
|
|
| Margaret Walters, Director of Pharmacovigilance at Merck Sharp & Dohme, helps us to navigate the difficult terrain of Pharmacovigilance in the EEA - An Overview of Requirements Impacting Industry |
|
|
| Customers are increasingly demanding instruments with Part 11-compliant software. Lynda J Bruce, Principal Engineer in the Life Sciences Business Unit and Annie LC Broadhurst, Technical Scholar at Cambridge Consultants Ltd, review Industry Trends in the Development and Provision of 21 CFR Part 11-Compatible Equipment |
|
|
|
|
| In Clinical Trials in Asthma, Dr Alan Davies, Therapeutic Director for Kendle International Inc, highlights the substantial financial and health rewards for those companies that can bring a novel product successfully to market |
|
|
|
|
| Bob Tilling, Director of New Business Development at MAP80 Systems Limited, keeps readers up-to-date, in How Clinical Trials Supplies Labelling May Be Affected by the Extended EU Local Language Requirements and How Integrated Labelling Systems Could Provide a Solution |
|
|
|
|
| In Maintaining a Spore-Free Environment in the Cleanroom, Suzanne Stubbs, Quality Manager at Shield Medicare Ltd, digests the strict requirements of EU good manufacturing practice for medicinal products |
|
|
|
| Dan Stevens, Marketing Manager, Life and Chemical Sciences at SGI, welcomes us to Visualisation in Drug Discovery: The Way of the Future |
|
|
| Traditionally restricted to treating the common cold and nasal allergies, nasal delivery is enjoying something of a renaissance. Per Gisle Djupesland, Head of R&D and Co-Founder of OptiNose AS, puts the question Who 'Nose' How Far Nasal Delivery Can Go? |
|
|
|
|
| Dr Miklos L Schulz, President and Senior Consultant, and St Clare Chung, Director of Biostatistics and Data Management at SciAn Services Inc, tackle The Next Major Hurdle for Electronic Data Capture: To Embrace Paper |
|
|
| Both pharmaceutical companies and CROs are keen to invest in electronic technology. Dr Uwe Albrecht, Managing Director of Mediconomics GmbH and CEO of Mediconomics Inc, analyses the benefits of Electronic Tools for Drug Development and Registration from a CRO's Perspective |
|
|
|
|
| Gijsbertus J Pronk PhD, Senior Director, US Business Development at Atugen AG, identifies New Approaches to Developing Cancer Drugs |
|
|
| In Improving Cancer Diagnosis and Prognosis Procedures, Dr Margaret Varga, Technical Leader, Imagery Systems, and Dr Michael McMillan, Channel Manager for Pharmaceuticals and Biotechnology at QinetiQ, establish the value of cancer network clinical information systems |
|
|
| Gerben Moolhuizen MBA and Leo GJ de Leede PhD at Octoplus, and Giulio F Paciotti PhD and Lawrence Tamarkin PhD of Cytimmune Sciences Inc, present Colloidal Gold Nanoparticles as a New Approach to Target Tumour Necrosis Factor to Solid Cancers |
|
|
|
|
| As a single agent does not cause asthma, discovery of a 'one size fits all' allergy vaccine is unrealistic. In Obstacles Ahead for Asthma Vaccines, Lisa Frawley, Respiratory Analyst at Datamonitor Healthcare pinpoints the issues |
|
|
|
|
| In Pharmacogenomics and the Impact on Central Laboratories, the need to meet procedural demands are discussed by Michelle Lynskey, Business Development Analyst at ICON Laboratories, Europe |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
